Bristol Myers' Admilparant Hits Primary Endpoint in Phase 3 IPF Trial
BMY sits 37% above its 52-week low of $42.52.
Summary
Bristol Myers Squibb's admilparant met the primary endpoint in the Phase 3 ALOFT-IPF trial for idiopathic pulmonary fibrosis. The 60 mg dose showed statistically significant improvement in forced vital capacity (FVC) at Week 52 versus placebo, with a favorable safety profile. The 120 mg dose slowed FVC decline but did not reach statistical significance. This is the first positive Phase 3 readout for admilparant in IPF, a disease with limited treatment options. Topline results from the companion ALOFT-PPF trial are expected in early 2027. Bristol Myers jumps as two late-stage trials deliver positive results.
At the time of this announcement, BMY was trading at $58.23 on NYSE in the Life Sciences sector, with a market capitalization of approximately $120.8B. The 52-week trading range was $42.52 to $68.64. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.